10x Genomics (NASDAQ:TXG) and Mettler-Toledo International (NYSE:MTD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.
Analyst Ratings
This is a summary of current ratings for 10x Genomics and Mettler-Toledo International, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| 10x Genomics | 0 | 1 | 7 | 0 | 2.88 |
| Mettler-Toledo International | 3 | 5 | 1 | 0 | 1.78 |
10x Genomics presently has a consensus price target of $181.4444, suggesting a potential downside of 6.78%. Mettler-Toledo International has a consensus price target of $971.3750, suggesting a potential downside of 20.54%. Given 10x Genomics' stronger consensus rating and higher possible upside, research analysts clearly believe 10x Genomics is more favorable than Mettler-Toledo International.
Profitability
This table compares 10x Genomics and Mettler-Toledo International's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| 10x Genomics | -51.27% | -19.98% | -14.38% |
| Mettler-Toledo International | 19.36% | 144.89% | 21.11% |
Institutional & Insider Ownership
68.8% of 10x Genomics shares are owned by institutional investors. Comparatively, 93.2% of Mettler-Toledo International shares are owned by institutional investors. 13.3% of 10x Genomics shares are owned by company insiders. Comparatively, 3.2% of Mettler-Toledo International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares 10x Genomics and Mettler-Toledo International's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| 10x Genomics | $245.89 million | 86.09 | $-31,250,000.00 | ($0.80) | -243.30 |
| Mettler-Toledo International | $3.01 billion | 9.48 | $561.11 million | $22.77 | 53.69 |
Mettler-Toledo International has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
10x Genomics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Summary
Mettler-Toledo International beats 10x Genomics on 8 of the 14 factors compared between the two stocks.
